enGene reported a higher net loss in Q1 2026 as operating expenses increased to support the LEGEND clinical trial and preparation for a planned BLA submission for detalimogene. The company maintains a strong balance sheet with over $312 million in cash and marketable securities expected to fund operations into the second half of 2028.

The company posted a Q4 net loss of $37.9 million as it continued investing heavily in clinical development and regulatory preparation. enGene ended the quarter with over $200 million in cash, bolstered by a recent financing round.

enGene posted a net loss of $28.9M in Q3 2025 as operating expenses nearly doubled year-over-year. Despite no revenue, the company achieved major milestones including full enrollment of its LEGEND pivotal cohort and RMAT designation for detalimogene.

enGene saw a significant increase in operating expenses in Q2 2025, resulting in a net loss of $25.8 million. The company emphasized progress in its pivotal LEGEND trial and reaffirmed its cash runway into 2027.

enGene Holdings Inc. reported a net loss of $24.6 million for the first quarter of 2025, an increase from $10.7 million in the same period last year, primarily due to increased operating expenses. The company expanded its LEGEND study sites into Europe and Asia, with enrollment in the pivotal cohort on track for a mid-2026 BLA filing. Cash and marketable securities of $272.8 million are expected to provide a runway into 2027.

enGene reported cash, cash equivalents and marketable securities of $297.9 million, which are expected to fund operations into 2027. The company also announced a BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026.

enGene Holdings Inc. announced its financial results for the third quarter ended July 31, 2024. The company's cash and cash equivalents were $257.7 million as of July 31, 2024, and expects this to fund operations into 2027. Net loss attributable to common shareholders was approximately $14.1 million, or $0.32 per share.

enGene reported its second quarter 2024 financial results, highlighting a net loss of $15.0 million, or $0.38 per share, and cash and cash equivalents of $264.8 million. The company is expanding the LEGEND study to include a cohort focused on enrollment of patients with high-risk, BCG-unresponsive papillary-only NMIBC.

enGene reported a net loss attributable to common shareholders of $10.7 million, or $0.46 per share, for the three months ended January 31, 2024. The company's cash and cash equivalents were $85.6 million as of January 31, 2024, and with the recent private placement, expects to fund operations into 2027.